Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Favipiravir (formerly T-705; T705; T 705; Avigan), an approved antiviral drug used to treat influenza in Japan, is a selective RNA-dependent RNA polymerase inhibitor. It is being researched for the treatment of other viral infections, including SARS-CoV-2, and has been used to treat influenza virus infections in Japan.
Targets |
RdRP ( IC50 = 341 nM )
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
Using the MTS-based CPE reduction assay in the MNV/RAW 264.7 cell line, the antiviral activity of Favipiravir (T 705) is assessed. Thus, 96-well plates containing 1×104 cells/well of RAW 264.7 cells are seeded, and MNV is injected at a multiplicity of infection (MOI) of 0.01, either with or without a dilution series of Favipiravir (T 705) (3.13-200 μg/mL). Once the infected cells have shown full CPE after three days of incubation, cell culture supernatants are obtained and used for quantitative real-time RT-PCR (qRT-PCR) to measure the viral RNA load. A stock solution consisting of 2 mg/mL MTS and 46 g/mL PMS in PBS at pH 6-6.5 is diluted 1/20 in MEM for the MTS reduction assay. The optical density (OD) is measured at 498 nm two hours after 75 μL of MTS/PMS solution is added to each well. In order to determine the percentage of CPE reduction, one must calculate [(ODtreated)MNW−ODVC]/[ODCC-ODVC]×100. In this calculation, ODCC denotes the OD of the untreated, uninfected cells, while ODVC and (ODtreated)CC stand for the treated, virus-infected cells and untreated, infected cells, respectively. The concentration of a compound that, in 50% of cases, prevented virus-induced CPE is known as the EC50. Favipiravir concentrations are applied to uninfected cells for three days in order to assess the molecule's detrimental effects on the host cell using the MTS-method.
The percentage of viable cells is computed as (ODtreated/ODCC)×100, where ODtreated refers to untreated uninfected cells treated with compound, and ODCC is the OD of untreated uninfected cells. The concentration of a compound at which 50% fewer viable cells are present is known as the CC50. CC50/EC50 is the formula used to compute the selectivity index (SI)[2].
|
|
Animal Protocol |
|
|
References |
Molecular Formula |
C5H4FN3O2
|
|
---|---|---|
Molecular Weight |
157.1
|
|
Exact Mass |
157.03
|
|
Elemental Analysis |
C, 38.23; H, 2.57; F, 12.09; N, 26.75; O, 20.37
|
|
CAS # |
259793-96-9
|
|
Appearance |
White to off-white solid powder
|
|
SMILES |
C1=C(N=C(C(=O)N1)C(=O)N)F
|
|
InChi Key |
ZCGNOVWYSGBHAU-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
|
|
Chemical Name |
5-fluoro-2-oxo-1H-pyrazine-3-carboxamide
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 6.3654 mL | 31.8269 mL | 63.6537 mL | |
5 mM | 1.2731 mL | 6.3654 mL | 12.7307 mL | |
10 mM | 0.6365 mL | 3.1827 mL | 6.3654 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05155527 | Recruiting | Drug: Ivermectin Tablets Other: Placebo |
COVID-19 | Mahidol University | February 10, 2022 | Phase 2 |
NCT06024421 | Not yet recruiting | Drug: favipiravir Drug: Placebo |
Infectious Disease Pharmacology |
Institut National de la Santé Et de la Recherche Médicale, France |
November 2023 | Phase 1 |
NCT05940545 | Recruiting | Drug: Favipiravir Drug: Ribavirin |
CCHF | Liverpool School of Tropical Medicine |
July 12, 2023 | Phase 1 Phase 2 |
NCT04376814 | Completed | Drug: Favipiravir Drug: Hydroxychloroquine |
COVID-19 Favipiravir |
Baqiyatallah Medical Sciences University |
March 29, 2020 | Not Applicable |
NCT04464408 | Completed | Drug: Favipiravir Drug: Placebo |
COVID-19 | King Abdullah International Medical Research Center |
July 23, 2020 | Phase 2 Phase 3 |